FDA says IBSPOT.com sold unapproved motion sickness patches containing diphenhydramine and diclofenac that the labels never listed.
What happened
FDA bought "Taoscare Motion Sickness Patch" and "Navabelle Motion Sickness Patches" through the company's website, www.ibspot.com, and had them tested in a laboratory. The tests found diphenhydramine, diphenhydramine N-oxide and diclofenac in the patches, none of which appear on the product labels. FDA cited the products as unapproved new drugs (drugs sold without FDA approval) and as misbranded (labeling that is false or misleading).
What FDA found
The patches are drugs sold without an FDA-approved application, which the law requires for new drugs.
Section 505(a) of the FD&C Act, 21 U.S.C. 355(a)The labels are false or misleading because they do not disclose that the patches contain diphenhydramine, diphenhydramine N-oxide or diclofenac, so consumers cannot check for allergies or drug interactions.
Section 502(a) of the FD&C Act, 21 U.S.C. 352(a)Shipping these unapproved drugs across state lines is a prohibited act.
Section 301(d) of the FD&C Act, 21 U.S.C. 331(d)Shipping these misbranded drugs across state lines is a prohibited act.
Section 301(a) of the FD&C Act, 21 U.S.C. 331(a)
What FDA wants
FDA asks the company to write within fifteen working days describing the specific steps taken to correct the violations and prevent them from happening again, with supporting documents, or to explain why it believes the products are not in violation. The reply goes by email to CDER's Office of Unapproved Drugs and Labeling Compliance at FDAAdvisory@fda.hhs.gov, with the firm name and identifier "715657" in the subject line.
Who should pay attention
- online marketplaces and web sellers listing third-party motion sickness patches
- brands selling anti-nausea or motion sickness patches
- importers and distributors of consumer drug products from overseas suppliers
This is a summary. Read the original letter on fda.gov.